SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Tularik Inc. (TLRK)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: mopgcw who wrote (398)1/29/2003 3:49:26 AM
From: mopgcw  Read Replies (1) of 598
 
CC summary:

2 new compounds in clinic;

4 tlrk discoverd in clinic + 2 partnered.

moved T607 to p2 -- moving along well; expect to complete this year;

t67 in pivotal; starting w/ 35 sites should be 75 by year end and will provide enrollment update at year end. Expect to enroll 1st patient soon. approval in many geographies --US/UK; still working on some -- should be on board later this year -- on track;

t131 begin p2a POC before year end and 1st data at ADA next year;

t487 staring multi-dose P1; P2a POC before year end; data early next year; no concern on safety after single dose trial; mult-dose run similar; safety data disclosed later this year;

1-2 new filing in 2003 from 6 candidates across 3 areas

have 100 targets; 30 leads;

Japan Tobacco; Sankyo & Medarex = future revs of 20-25 mm (incl some new stuff);

expenses increased from acquisiton last year and some growth in cumbre;

2 years of cash;

29 oncogenes identified; 1/2 small molecule; 1/2 antibody; a number of antibody in research moving to clinic in 2004;

only MS and GS asked questions.

I bought more at 4.75, so the price will go down to $2 for sure.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News